Petros Pharmaceuticals (NASDAQ:PTPI) Shares Down 4.5% – Time to Sell?

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI)’s stock price was down 4.5% during mid-day trading on Tuesday . The stock traded as low as $0.28 and last traded at $0.29. Approximately 138,418 shares were traded during trading, a decline of 74% from the average daily volume of 529,558 shares. The stock had previously closed at $0.30.

Petros Pharmaceuticals Stock Down 4.6 %

The company has a quick ratio of 1.26, a current ratio of 1.40 and a debt-to-equity ratio of 0.71. The company has a fifty day simple moving average of $0.34 and a 200-day simple moving average of $0.42. The firm has a market cap of $2.71 million, a P/E ratio of -0.04 and a beta of 2.11.

Petros Pharmaceuticals (NASDAQ:PTPI) last released its earnings results on Wednesday, August 14th. The company reported ($0.37) earnings per share (EPS) for the quarter. The company had revenue of $1.42 million for the quarter.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).